Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TETRALITE
- Development stage
- Phase 2
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**TETRALITE** is an investigational adjuvanted seasonal influenza vaccine developed by LiteVax. The product combines a licensed inactivated seasonal influenza vaccine with LiteVax Adjuvant, a synthetic carbohydrate fatty-acid monosulphate ester formulated on squalane-in-water emulsion nanodroplets. The first-in-human study evaluated one-fifth of the standard licensed-vaccine antigen dose with low or high adjuvant doses; a subsequent study evaluated LiteVax Adjuvant added to a full licensed-vaccine dose in adults and older adults. It is intended to enhance influenza vaccine immunogenicity while potentially reducing antigen requirements. ([litevax.com](https://www.litevax.com/wp-content/uploads/PR-TETRA-LITE.pdf))
- Brand names
- TETRALITE
- Other names
- TETRA-LITETETRALITE
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on TETRALITE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TETRALITE.